60例活动性肝硬变患者血清载脂蛋白AI与B的临床研究

目的：为了探讨活动性肝硬变患者的血清载脂蛋白AI（APOAI）、载脂蛋白B（APOB）与肝细胞损害的严重程度及其预后的关系。方法：采和速度比浊法检测60例活动性肝硬变患者的血清APOAI、APOB水平，并与其他肝脏生化试验进行比较。结果：活动肝硬变代偿性与失代偿性两组APOAI，APOB均有着显著性差异（P＜0．01，P＜0．05）。活动性肝硬变患者的APOAI与总胆红素（TB）、凝血酶原时间（PT）呈负相关性（P＜0．01，P＜0．01，与白蛋白（ALB），胆碱酯酶（CHE）、纤维蛋白原（FIB）呈显著正相关性（P＜0．01，P＜0．01，P＜0．05）。APOX仅与FIB呈显著相关性（P＜0．05），好转组与死亡组两组APOAI有显著性差异（P＜0．05），APOB无显著性差异，结论：检测活动性肝硬变患者血清APOAI，APOB水平有助于判断肝硬变的严重程度，且APOAI比APOB更敏感、可靠。

The clinical study of serum Apolipoprotein AI and B in 60cases active liver cirrhosis

Objective: It is to explore the relationship between serum the APOAI, APOB and the serious extent of liver call harm, and it effect on the prognosis of the active liver cirrhosis. Methods; 60 cases of active liver cirrhosis were subjected to this test by using rate-turbidimetry. Their serum APOAI, APOB were determined and compared to other liver biochemistry test. Results; There is a marked difference in the level of APOAI, APOB of the compensation group and the decompensation one of the liver cirrhosis (P<0. 01, F<0. 05). For patients of active liver cirrhosis, there is a marked negative relationship between APOAI to TB and PT (P<0. 01, P<0. 01) and a marked positive relationship to ALB. CHE and FIB (P<0. 01, P<0. 01, P<0. 05). There is a marked positive relationship between APOB and FIB (P<0. 05). To the improve group and death group. There is a marked difference in APOAI, while the APOB nomarked difference. Conclusion; For the case of active liver cirrhosis, the determination of serum APOAI, APOB may judge the patient's serious extent and marke prognosis, while the APOAI is more sensitive and reliable.